Sector News

Merck joins Novartis, GlaxoSmithKline in grabbing a consumer executive to beef up digital

October 18, 2018
Life sciences

Merck & Co. is joining the chief digital officer parade. The pharma giant has poached Jim Scholefield from Nike to head up its global IT and digital strategy, becoming the latest Big Pharma to put digital on its priority list.

Scholefield will serve on Merck’s executive committee, underscoring the company’s bid to thread new digital and IT work into its operations, from R&D to commercial. Judging by a reference in its hiring announcement, he’ll also take on cybersecurity, a need Merck knows all too well. Last year’s notPetya attack disrupted manufacturing and R&D, caused some supply issues and cost Merck nearly $1 billion.

The Merck hire is part of a surge of pharma interest in using digital and data technology to speed up drug development, make marketing more efficient and effective and boost productivity all the way around. The industry is late to the party—as is often the case with overall business trends—but the action has been heavy, and high hopes come along with it.

Scholefield follows close on the heels of a similar executive addition at Pfizer, which recruited Quest Diagnostics’ chief information officer for its executive ranks. His hire was part of a reshuffling earlier this month as incoming CEO Albert Bourla assembles his own team.

And in moves more closely mirroring Merck’s, Novartis and GlaxoSmithKline each plucked consumer executives for their digital teams. Novartis brought in Bertrand Bodson from the retail industry last August to head up its digital efforts. In March, the Swiss drugmaker’s new CEO, Vas Narasimhan, promoted Bodson to his executive committee, citing digital and data as top priorities. GSK chief Emma Walmsley snagged a former Walmart Stores exec to help the company harness IT and digital to augment its own transformation.

Scholefield’s resume includes spearheading a “digital transformation” at Nike, Merck said in announcing its new exec—and one of his accomplishments was delivering “state-of-the art cyber-security,” the company said.

“His extensive experience leading large global IT organizations for multinational companies, including developing innovative digital capabilities, makes him an exceptional addition to our team,” Robert Davis, Merck’s CFO and executive vice president of global services, said in the statement.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).